FOLFIRI regimen as second-line treatment of metastatic gastric cancer: a retrospective analysis of efficacy, safety and prognostic factors
Keywords:
FOLFIRI, second-line, metastatic gastric cancer, prognostic factorsAbstract
Background: There is no standard second-line treatment for mGC. FOLFIRI has shown efficacy and safety in this setting. Methods: Retrospective study of patients with mGC treated with FOLFIRI as a second line. We evaluated the response rate (RR), clinical benefit rate (CBR), progression-free survival (PFS), OS and toxicity. Results: Sixty-six patients were included. Among evaluable patients there was an overall response rate of 20% and stable disease in 34%. Median PFS was 3 months and median OS 6 months. The number of metastatic sites was found to be a prognostic factor for PFS (HR 2.23; p=0.005) and OS (HR 2.71; p<0.001). PFS in the first line was a prognostic factor for OS (HR 1.71; p=0.045), but not for PFS (HR 1.37; p=0.226). PFS in the first line <7 months and ≥2 metastatic sites were identified as poor prognostic factors. We defined two prognostic groups, with patients in the poor prognostic group having worse PFS (HR 2.08; p=0.030) and OS (HR 2.97; p=0.003). The most common grade 3-4 toxicity was neutropenia 27%. Conclusions: FOLFIRI is effective and well-tolerated as a second-line treatment in mGC. The number of metastatic sites and PFS in the first line are prognostic factors in this group of patients.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.